OUR

CONCERN CONQUERS!

Concern Foundation
Funding Cancer Research Worldwide
As the days, weeks, months and years continue to whirl by with new trends and constant changes, two things remain the same: cancer is still one of the largest killers in the world, and Concern Foundation continues to be steadfast in our commitment to eradicate cancer.

In 1968, Concern Foundation believed that investing in the growing careers of young innovative researchers within the field of cancer immunology was the future and that the immune system, once understood, would someday be used to treat and control cancer. Today, we have the proof that “someday” is today!

If you ask any oncologist, they’d tell you that they, too, believe that the immune system can have a role in the progression of treatment, and possibly a role in treating cancer. Hospitals and pharmaceutical companies who had no interest in immunotherapy have now invested in and developed immune-oncology departments as well as immunotherapy programs.

Even the general public today more clearly understands what immunotherapy is, and that there is hope for defeating this disease by using immunotherapies. In a very short period of time the idea of immunotherapy has become very empowering because patients are using their own immune system to recognize and destroy the cancer in their bodies.

It is with great pride and complete confidence that I can tell you, our donor, that we are funding cutting edge projects and the next generation of top-of-the-line scientists who are investigating this area of cancer research, thanks to Concern’s Scientific Review Committee. These men and women are in the best in their field and their guidance and commitment to helping us fund the next generation of cancer researchers is second to none.

Sincerely,

Derek Alpert
President
WHAT

Concern Foundation’s mission is to fund innovative research worldwide in the quest to conquer cancer. Since its founding in 1968, Concern has been a pioneer in the advancement of cancer immunology—the study of the relationship between the immune system and cancer. Our objective is to further the careers of gifted young cancer researchers (Assistant Professor or equivalent) whose work shows great promise, but may not be sufficiently advanced enough in their careers to justify funding from the government or other major funding sources. We focus on finding the most talented scientists with brilliant approaches to unlocking the mystery of cancer.

WHY

“We have reached the point of diminishing returns with the available cancer therapies...it is no longer acceptable in the 21st century to deliver more chemotherapy or radiation. New, novel therapies are necessary.”

Laurence Cooper, Scientific Review Committee member, perhaps said it best when he stated the importance of providing start up grants to young investigators. Concern Foundation helps to bridge a critical gap in much-needed research funding, and we believe that this unique approach will continue to fuel progress and effective therapies in the treatment of cancer. For 48 years, Concern Foundation has made it possible to transform new ideas from the mind of a researcher into groundbreaking innovations in cancer research.

HOW

New grant proposals are accepted every two years and undergo a rigorous peer review process. Potential applicants are pre-screened with a Letter of Intent, which ensures that only qualified investigators complete the thorough and detailed grant application. Each application is then administratively reviewed. A primary and secondary review follows by Concern Foundation’s Scientific Review Committee. Those applications that advance through these stringent levels are then discussed in further detail at the biennial Scientific Review Committee meeting.

Concern Foundation strives to recruit a cross-section of new and established cancer researchers who comprise our renowned Scientific Review Committee. These exceptional men and women guide our grant review process and help us select the top researchers from a competitive pool of applicants.

Each grant recipient is awarded a $60,000 grant. Provided that sufficient progress is achieved in the first year, Concern awards a second year grant of $60,000. It is the Foundation’s hope that after two years of funding, Concern-sponsored researchers go on to publish their findings in major journals, obtain larger awards to further their work, and advance their positions at respected institutions across the United States and abroad.
Scott Atwood
University of California, Irvine
Skin Cancer
FAT1 regulates basal cell carcinoma initiation and drug resistance

Luis Batista
Washington University in St. Louis
Liver Cancer
Telomerase modulation prevents end stage liver disease and cancer

Milan Chheda
Washington University in St. Louis
Brain Cancer
Chromatin remodeling in glioblastoma

Saar Gill
University of Pennsylvania
Ovarian Cancer
Chimeric antigen receptor-redirected macrophages for solid tumors

Bojana Gligorijevic
Temple University
Breast Cancer
Real-time intravital imaging of cancer cell cycle and motility states

Xi Huang
The Hospital for Sick Children, Toronto Canada
Brain Cancer
Targeting EAG2 potassium channel in glioblastoma

Hyungiin Kim
State University of New York, Stony Brook
General Cancer Mechanism
Mechanisms linking proteolysis to replication stress and tumorigenesis

Kian-Huat Lim
Washington University in St. Louis
Pancreatic Cancer
Neutralizing the innate immune defense mechanism of pancreatic cancer

Chintan Parekh
Children’s Hospital Los Angeles
Leukemia
Role of the long noncoding RNA DANCR in T cell acute lymphoblastic leukemia

Olga Razorenova
University of California, Irvine
Breast Cancer
Dissecting the role of CDCP1 in pro-metastatic signaling

Bruno Sainz
Universidad Autónoma de Madrid (Autonoma University Of Madrid)
Pancreatic Cancer
Targeting mitochondrial respiration, an Achilles’ heel of cancer stem cells

Masataka Suzuki
Baylor College Of Medicine
Head & Neck Cancer
Combining ad gene therapy with car ad-specific t-cell therapy for HNSCC

Baochun Zhang
Dana-Farber Cancer Institute
Lymphoma
Dual specificity phosphatase 2 in diffuse large B-cell lymphomagenesis
**PEDIATRIC CANCER – BRAIN TUMOR**  
Anat Epstein  
Children’s Hospital Los Angeles  
Novel Molecular Model of P1D1 Function in Pediatric Brain Tumors  
*Funding matched by Mrs. Mimi Feldman & NSBN LLP*

**ADOLESCENT & YOUNG ADULT CANCERS**  
The Adolescent and Young Adult Program (AYA@USC) at USC Norris Comprehensive Cancer Center & Children’s Hospital Los Angeles  
Tissue Registry, Social Worker & Data Coordinator  
*This grant is co-funded by Marion Brucker Legacy Fund*

**TESTICULAR CANCER**  
The Adolescent And Young Adult (AYA@USC) Program in partnership with Los Angeles Unified School District  
Pilot Testicular Cancer project for early detection/self-examinations by students  
*This grant funded by a portion of the proceeds raised during the 2016 LA Marathon*

**POPULATION SCIENCES – SECONDARY CANCER DEVELOPMENT**  
Julie Wolfson, M.D.  
City of Hope  
Disparities in Adolescent & Young Adult Cancers  
*Funding matched by the Teller & Shapiro Family*

**CONCERN FOUNDATION STEM CELL RESEARCH AWARD**  
Dr. Amander Clark, PhD  
UCLA Broad Stem Cell Research Center  
Conquering Germ Cell Tumors in Children and Young Adults  
*This grant is co-funded by Wendy & Tom Nogradi and NSBN LLP*

**PROSTATE CANCER**  
Dr. Jeremy Jones  
City of Hope  
Understanding the Relationship between Low Testosterone & Prostate Cancer Risk  
*This grant is co-funded Myrna & Stanley Zimmerman and the Marion Brucker Legacy Fund*

**PROSTATE CANCER**  
Dr. Owen Witte  
UCLA Broad Stem Cell Research Center  
Identification and Functional Characterization of Kinases Driving Prostate Cancer Metastasis to Bone  
*This grant is funded through Concern by Myrna & Stanley Zimmerman*
Glioblastoma is the most aggressive brain tumor. One reason these tumors inevitably recur—typically within six months of radiation and chemotherapy—is that there exist tumor cells that are resistant to radiation and chemotherapy.

Our focus has been on understanding how a protein, CHD4, protects these cancer cells, sometimes known as cancer stem cells. CHD4 is a member of the nucleosome remodeling and deacetylase (NuRD) complex. CHD4, NuRD, and more generally, the cancer stem cell state, are the focus of our Concern Foundation-funded work. We have made extensive progress this past year.

We found that CHD4 is required for growth and survival of cancer cells but not normal cells. To understand the potential consequences of CHD4 depletion in the setting of DNA damage, we hypothesized that CHD4 suppression alone prolongs DNA damage in tumor cells, but not normal cells. Indeed, we observed that CHD4 suppression is associated with gamma H2AX expression, specifically in cancer cells. This will form the basis of further exciting experiments to test whether there exists a synergy between radiation-induced DNA damage and the damage and decreased viability we observe with CHD4 suppression.

Through serendipity and strong collaborations, our Concern Foundation-funded work has also led to a potential new use for pathogenic viruses to kill glioblastoma cells. In particular, we have found that glioblastoma stem cells (GSCs) are more susceptible to Zika virus-mediated death, than are their differentiated counterparts, differentiated glioma cells (GDCs).

We are testing the effects of Zika virus (ZIKV) on murine models of glioblastoma. We have preliminary evidence that the administration of a mouse-adapted Zika virus prolongs survival. We are very enthusiastic about this work advancing a new therapeutic modality for glioblastoma. Further investigations will test whether NuRD members play a role in driving gene-expression programs responsible for cancer stem cell-susceptibility to ZIKV.

Together, these studies have advanced our understanding of glioblastoma and have already opened several avenues to pursue for improving therapies for brain tumors.
For over forty years, Concern Foundation has been proud to support the fine work of the Lautenberg Center. This annual endowment is supported by a generous grant from the Ahmanson Foundation. The following page summarizes the incredible work of just two of our funded cancer immunology researchers at the Lautenberg Center.

**BELOW ARE THE SCIENTISTS CURRENTLY SUPPORTED BY THE CONCERN FOUNDATION ENDOWMENT:**

<table>
<thead>
<tr>
<th>Rami I. Aqeilan</th>
<th>Michael Berger</th>
<th>David Naor</th>
<th>Eitan Yefenof</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michal Baniyash</td>
<td>Moshe Kotler</td>
<td>Oren Parnas</td>
<td>Eli Pikarsky</td>
</tr>
<tr>
<td>Yinon Ben-Neriah</td>
<td>Ofer Mandelboim</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Molecular Rationale for Steroid Based Therapy of Leukemia: Basic and Clinical Implications

Professor Eitan Yefenof

Glucocorticoid hormones (GCs), such as prednisone and Dexamethasone, are an essential component in the therapy of lymphoma and lymphoid leukemia since they induce apoptotic death of lymphoid cells, whether normal or malignant. A major impediment in GC therapy is the gradual acquisition of resistance to the drug due to repeated treatments. Indeed, relapsed patients are usually resistant to GC therapy. Therefore, it is of great importance to study the mechanism of GC-sensitivity and the mode by which cancerous cells acquire GC-resistance in order to improve lymphoma and lymphoid leukemia therapy.

Cells respond to GC because they contain a protein that acts as a receptor for GC (GR). Upon binding of GC, the GR undergoes a series of modifications and then enters the cell nucleus were it affects the expression of multiple genes. However, these events occur in both sensitive and resistant leukemia cells. Indeed, most of the GR regulated genes are not related to apoptotic death.

Numerous studies were performed in order to decipher the mechanism that distinguishes between GC-sensitive and GC-resistant cells. While GR nuclear activities occur in both GC-sensitive and GC-resistant cells, the gene expression profile is partially different. Several apoptosis related genes were found to be regulated in GC-sensitive- but not in GC-resistant cells. Of special note are the up-regulation of the GR and the pro-apoptotic Bim, as opposed to the down-regulation of the pro-oncogenic c-Myc.

GR also regulates microRNAs (miRs) gene expression, such as the miR-15∼16 cluster and the miR-17892a poly-cistron. We have performed deep sequencing analysis for detection of miRs that are affected by GC treatment. Fourteen miRs were found to be regulated by GC treatment of sensitive cells. miR-103 stood out as being up-regulated in correlation with the death response of GC sensitive leukemias.

Consequently, we have launch on a translational project with a focus on miR-103 as a diagnostic therapeutic tool in the treatment of lymphoma and lymphoid leukemia. These projects are advanced in collaboration with the department of pediatric hemato-oncology at Hadassah Medical Center. The translational studies have been enabled by financial support provided by Yissum and the Ministry of Economics.

Molecular and Cellular Characterization of Dysregulated Tumor Suppressors and Oncogenes Involved in Cancer

Professor Rami I. Aqeilan

Cancer is one of the leading causes of human death in the world. Mounting evidence strongly suggests that loss of function of tumor suppressor genes and gain of function of oncogenes are mainly responsible, not only for the development and progression of cancers, but also for the sensitivity of cancer patients to radiation and chemotherapeutic drug treatments. Therefore, understanding the molecular and cellular function of these genes/pathways is essential for cancer diagnosis and therapy.

In our lab, we focus our work on deciphering the function of novel tumor suppressors and oncogenes and exploring the possibility of normalizing these genes in cancer cells; specifically, in breast and pancreatic cancer as well as pediatric osteosarcoma. Recently, we became interested in studying a novel group of non-coding genes, named microRNAs. microRNAs are small RNA molecules that regulate gene expression and are involved in multiple cellular pathways including those implicated in cancer. In our lab, we study the role of cancer-associated microRNAs in the pathogenesis of breast cancer and osteosarcoma.

Further, we study a group of genes spanning “sensitive” genomic regions that are thought to be linked with cancer development. These regions are called common fragile sites (CFSs) due to inherent fragility that make them function as sensors of DNA damage. CFSs are thought to be involved in early cancer stages and hence, we study their molecular involvement in cancer initiation and progression.

One central gene that we study in the lab is WW domain-containing oxidoreductase (WWOX), which encodes a tumor suppressor. Our work attempts to uncover the molecular function of this protein and others, and the mechanism it might play in cancer. One of the main aims is to discover the molecular and signaling pathways that involve these genes and learn whether therapeutic and clinical modules can be achieved. By doing so, we hope to shed light on the requirement of tumor suppressors and proto-oncogenes for the normal function of the cell and better learn about what goes wrong in disease state, such as in cancer.

Overall, our work attempts to characterize novel functions of dysregulated genes that might help in cancer intervention.
CONCERN FONDLY REMEMBERS

In Memoriam

George Klein, MD, PhD
Karolinska Institute

At the end of 2016, George Klein, MD, PhD, professor emeritus of tumor biology at the Karolinska Institutet in Stockholm, passed away at the age of 91.

Dr. Klein, who collaborated with his wife, Eva Klein, MD, PhD, FAACR, for most of his long and notable career, was at the forefront of significant advances in tumor biology and immunology. Since 1981, Concern Foundation has provided 188 cancer research scientists in his laboratory funding from an annual award that is matched by Cancer Research Institute in New York.

A survivor of the Holocaust, Dr. Klein settled in Sweden in 1947, where he completed his medical degree and PhD. He received a personal professorship in tumor biology at the Karolinska Institutet, launching a lifetime of service to science. From his “retirement” in 1993 until his death, he was a research team leader at the Department of Microbiology, Tumor and Cell Biology, MTC, at Karolinska Institutet.

Dr. Klein received numerous honors throughout his career, including the 1979 Alfred P. Sloan, Jr., Prize of the General Motors Cancer Research Foundation for his pioneering work on the interrelation of cancer and the immune system. He was a member of the Royal Swedish Academy of Sciences, the Karolinska Institutet’s Nobel Assembly (1957-1993), and the U.S. National Academy of Sciences.

Not only was he an active member of the Concern Foundation Scientific Review, but he was a good friend of the organization, who will fondly be remembered and celebrated.

Dr. David Weiss
Lautenberg Center at Hebrew University

Dr. David Weiss, Concern’s first funded researcher and the founder of the Lautenberg Center, died on July 12, 2016.

Dr. Weiss established the Lautenberg Center for General and Tumor Immunology and served as its first Director until 1996. Over the years, David recruited resources and personnel for the center and structured it to be a cutting edge and leading institution for research and teaching. David was a leading scientist in the arena of cancer immunology and immunotherapy with more than 200 publications in scientific journals and books.

Since 1971, Concern Foundation has been proud to support the fine work of the Lautenberg Center. Our annual direct gift, along with a generous matching grant from the Ahmanson Foundation and the interest and earnings from an endowment that was set up by Concern nearly 40 years ago, is used to support the ongoing work of the Lautenberg Center. Today there are ten full-time scientists and a multitude of graduate students and junior faculty members who are currently supported by funding from Concern Foundation.

David Weiss shall be remembered as a great researcher, teacher, writer and speaker who left an unforgettable signature on the quality of science performed by Lautenberg Center scientists.
Raising Funds & Awareness for Cancer Research

2016 LA Marathon

Concern Foundation joined the Los Angeles Marathon as an official charity for the seventh consecutive year, and is thrilled to announce a record-breaking $160,000 was raised by its dedicated team!

On Valentine’s Day, 16 runners and walkers took to the streets of LA and conquered the famed Stadium to the Sea marathon course, even braving record high temperatures to boot. Many of our runners were new to Team Concern this year; Team Concern veteran Patrick Baker brought a team of five high school runners all the way from sunny Hawaii. At only 16 and 17 years old, these dedicated athletes ran their very first marathon and finished with flying colors.

Patrick and his team were first introduced to Concern Foundation through our collaboration with the Adolescent and Young Adult Program at USC Norris Comprehensive Cancer Center (AYA@USC). By joining forces with Concern in recruiting runners and raising funds toward the marathon campaign, AYA was awarded a $50,000 grant to support its program which focuses on providing treatment, emotional needs and social support for teens and young adults with cancer.

“It was so great to witness these kids give back and work hard to reach a personal goal. It really was one of the best teaching moments in my 16 year career,” says Patrick.

Saturday February 13 was the LA BIG 5K at Dodger Stadium, where more than 40 runners and walkers represented Team Concern.

We’re so proud of Team Concern and all of the athletes who tirelessly trained and fundraised on our behalf. It’s an honor to be chosen as their charity of choice, and we promise that all of the money raised will be committed to innovative and life-saving cancer research.

Cycle With Soul Charity Ride

Concern Foundation hosted its third annual Cycle With Soul event on September 24 in Beverly Hills. The charity ride and fundraiser raised nearly $30,000 for cancer research.

SoulCycle, the popular cycling fitness craze, was introduced to Concern by young board member Courtney Teller, who led the event to success once again. Sponsors included Anxiety Therapy LA, Hollywood Printing & Embroidery and Personal Dental. The event concluded with refreshments and snacks provided by Juice Crafters in Brentwood and Treate cookies.

Cycle with Soul has grown immensely in the last three years. This year, we had the pleasure of a live performance by popular musician Spencer Ludwig.

Concern board member and Cycle With Soul Participant, Allie Lehrman, said it best: “There is nothing like being in a room of amazing humans leaving their egos at the door, not caring how their makeup looked or if their hair was perfect, coming together for the same cause. We showed up for each other, for our families, friends and strangers around the world to do our part to get closer to a cancer free world.”

NSBN LLP Annual Charity Golf Tournament

On November 14, 2016 Concern was the beneficiary of NSBN’s Annual Charity Golf Tournament, which raised $85,000 for cancer research.

The money raised by the golf tournament was granted by Concern to two different research projects in Los Angeles. The first was a brain tumor research project at Children’s Hospital Los Angeles, led by Dr. Anat Epstein. The Adolescent and Young Adult Cancer Program (AYA@USC) at USC’s Keck Medical Center also received a research grant.

This was Concern Foundation’s third year partnering with NSBN, and in total we have raised over $120,000 for cancer research. We are thankful to board member Allie Lehrman for connecting us with the firm, and we look forward to our continued partnership with the firm.
Day for the Kids at Universal Studios

October 16, 2016

As always, we had an amazing time at Universal Studios Hollywood for our annual Day for the Kids on October 16. It really is a remarkable day enjoyed by patients, friends, family and volunteers.

This year we visited the brand-new Wizarding World of Harry Potter—a favorite for many of our guests—had a delicious lunch catered by Universal Studios and spent all afternoon exploring the park.

We owe a debt of gratitude to our friends at Universal Studios' Discover A Star Foundation for generously donating this wonderful opportunity for the last 28 years, and to our volunteers who truly make this day so special. Concern is very honored to be a part of this incredible day, and we look forward to many more years with Universal.

Hawaiian Holiday Party at Paramount Pictures

December 11, 2016

Concern Foundation’s 29th annual Holiday Party at Paramount Studios on December 11 was a huge success. We loved welcoming hundreds of pediatric cancer patients and their families for a day filled with Santa sightings, Disney's Moana, good food, great activities and even better company.

This year we welcomed Rita’s Italian Ice to the party—they were a smash hit! The kids always love having Beauty Bus Foundation there to get a new hairstyle and a makeover. Our favorite hot dogs from Factor’s Famous Deli had a line around the whole party until they ran out! The day wouldn’t be the same without 3D Cheeze Flip Photos, Island Ink tattoos, Brian Kramer Photography and of course, Santa Claus. We have Town & Country Event Rentals, Paramount Pictures Studios and all our wonderful volunteers to thank for this very special day!
## CONSOLIDATED STATEMENT OF FINANCIAL POSITION

**December 31, 2016**

### ASSETS

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>$638,433</td>
</tr>
<tr>
<td>Operating investments</td>
<td>$1,701,468</td>
</tr>
<tr>
<td>Pledges receivable, net</td>
<td>$336,284</td>
</tr>
<tr>
<td>Beneficial interest in charitable remainder trusts</td>
<td>$231,867</td>
</tr>
<tr>
<td>Property and equipment, net</td>
<td>$8,057</td>
</tr>
<tr>
<td>Endowment investments</td>
<td>$1,991,292</td>
</tr>
<tr>
<td>Other assets</td>
<td>$34,240</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td><strong>$4,941,641</strong></td>
</tr>
</tbody>
</table>

### LIABILITIES AND NET ASSETS

#### Liabilities

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>$35,700</td>
</tr>
<tr>
<td>Grants payable</td>
<td>$497,500</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>$643,034</td>
</tr>
<tr>
<td><strong>Total liabilities</strong></td>
<td><strong>$1,176,234</strong></td>
</tr>
</tbody>
</table>

#### Net assets

- **Unrestricted**
  - Undesignated                                           | $200,000|
  - Board-designated                                       | $1,322,205|
- **Total unrestricted**                                   | **$1,522,205**|
- Temporarily restricted                                   | $322,830 |
- Permanently restricted                                   | $1,920,372|
- **Total net assets**                                     | **$3,765,407**|

**Total liabilities and net assets**                       | **$4,941,641**|
## CONCERN FOUNDATION AND SUBSIDIARY
### CONSOLIDATED STATEMENT OF ACTIVITIES
#### Year Ended December 31, 2016

<table>
<thead>
<tr>
<th>Revenue and support</th>
<th>Unrestricted</th>
<th>Temporarily Restricted</th>
<th>Permanently Restricted</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contributions</td>
<td>$ 15,003</td>
<td>$ 282,500</td>
<td>$</td>
<td>$ 297,503</td>
</tr>
<tr>
<td>Special events, net</td>
<td>1,293,021</td>
<td>30,000</td>
<td>-</td>
<td>1,323,021</td>
</tr>
<tr>
<td>Campaign</td>
<td>23,498</td>
<td>-</td>
<td>-</td>
<td>23,498</td>
</tr>
<tr>
<td>Investment income</td>
<td>43,200</td>
<td>45,817</td>
<td>-</td>
<td>89,017</td>
</tr>
<tr>
<td>Change in value of charitable remainder trusts</td>
<td>-</td>
<td>(492)</td>
<td>-</td>
<td>(492)</td>
</tr>
<tr>
<td>Net realized and unrealized gains on investments</td>
<td>68,014</td>
<td>-</td>
<td>-</td>
<td>68,014</td>
</tr>
<tr>
<td>Net assets released from restrictions</td>
<td>312,861</td>
<td>(312,861)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Total revenue and support</strong></td>
<td>1,755,597</td>
<td>44,964</td>
<td>-</td>
<td>1,800,561</td>
</tr>
</tbody>
</table>

| Expenses                                |              |                        |                        |       |
| Program services                        | 1,404,377    | -                      | -                      | 1,404,377 |
| Management and general                  | 134,240      | -                      | -                      | 134,240 |
| Fundraising                             | 189,832      | -                      | -                      | 189,832 |
| **Total expenses**                      | 1,728,449    | -                      | -                      | 1,728,449 |
| Change in net assets                    | 27,148       | 44,964                 | -                      | 72,112 |
| Net assets, beginning of year           | 1,496,057    | 277,866                | 1,920,372              | 3,693,295 |
| Net assets, end of year                 | $ 1,522,205  | $ 322,830              | $ 1,920,372            | $ 3,765,407 |
Ilyse Teller, Chair
Derek Alpert, President
Nancy Eisenstadt, Vice Chair
Michael Firestein, Secretary/Legal Counsel
Marc Lauter, Chief Financial Officer

Anne Barnett
Bill Barnett
Harvey Beesen
Shelby Blecker
Nancy Blecker
Barry Brucker
Sue Brucker
John Carroll
Lexy Carroll
Carla Daly
David Entin
Steve Fortner
Lynne Fox
Steve Freed
Jim Freedman
Alan Gittelson
Nancy Gittelson
Robert Goldman
Lorene Goldman
Aliza Goldsmith
Noah Goldsmith
Jackie Gottlieb
Stanley Gottlieb
Allie Lehrman

Max Liszt
Marc Luber
Eric Massi
Michelle Massi
Ian Metrose
Lauri Metrose
Frank Mottek
Jessica Nicastro
Wendy Nogradi
Tom Nogradi
Debbie Powell
Rick Powell
Joyce Powell
Larry Powell
Laurie Resch
Dana Schwartz
Courtney Teller
Steve Teller
Steve Ullman
Briana Vickers
Scott Vickers
Myrna Zimmerman
Stan Zimmerman
GET INVOLVED WITH CONCERN FOUNDATION

Concern Foundation has raised over $58 Million to fund cancer research through donations from individuals like yourself! Help us **CONquer can**CER **N**ow.

- Make a monetary donation today.
- Become an Annual Sponsor and enjoy sponsorship benefits
- Send a tribute in honor or in memory of someone special
- Be a part of our signature Block Party fund raising event
- Start your own fundraiser
- Be a part of Team Concern by participating in the LA marathon or another athletic event or activity of your choice
- Take steps to create a planned gift
- Donate your time and expertise by volunteering
- Get your place of business involved and become a community partner or corporate sponsor
- Help spread the word about Concern Foundation

Each year, 14 million men, women, and children worldwide are diagnosed with some type of cancer. Continued research to find better, smarter, more effective treatments is urgently needed. Only with your help can we continue to fund innovative research and bring breakthrough treatments and “cures” to more cancer patients.